

Kazia Therapeutics Ltd

21:19 12 Aug 2019

Kazia Therapeutics concludes recruitment into Part B of its phase I ovarian cancer clinical study

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) has completed the recruitment of patients into Part B of its phase I clinical study of Cantrixil in ovarian cancer.

Cantrixil is a third-generation benzopyran molecule with activity against cancer stem cells and is being developed to treat ovarian cancer.

Background

Part A of the study collected data from an initial 14 patients, who received escalating doses of Cantrixil to determine safety and tolerability.

A maximum tolerated dose of 5 mg/kg was achieved, and this data was reported at the American Association of Cancer Research conference on April 1 2019.

Final completion of the study in 2020

Part B was designed to enroll 12 patients, all of whom will receive Cantrixil at a dose of 5 mg/kg. Part B will seek preliminary signals of potential efficacy for the drug.

Initial data from Part B is expected in the fourth quarter of calendar 2019, with final completion of the study in 2020.

Kazia chief executive officer Dr James Garner said: "Part B of the Cantrixil study has recruited well and we are now following patients through to completion of their treatment.

"We are grateful for the excellent efforts of the participating clinicians, and of the study team. The first part of the study has shown some very promising signals, and the data from Part B will significantly enhance our understanding of the drug.

"We will be presenting data at the ESMO conference at the end of September, and this will be valuable opportunity to move forward our partnering discussions for Cantrixil."

Low survival rate for ovarian cancer

About 240,000 women are diagnosed with ovarian cancer each year worldwide and it is the eighth most common cause of cancer death in women.

Conventional treatment typically includes surgery, radiotherapy, and chemotherapy.

Price: A\$0.35

Market Cap: A\$23001700M

1 Year Share Price Graph



Share Information

Code: KZA

Listing: ASX

52 week High Low
A\$0.60 A\$0.32

Sector: Pharma & Biotech

Website: www.kaziatherapeutics.com

Company Synopsis:

Kazia Therapeutics (ASX: KZA, NASDAQ: KZIA) pipeline includes two clinical-stage drug development candidates.

action@proactiveinvestors.com

However, the five-year survival rate remains low, at about 45%, reflecting the fact that the disease is often advanced at the time of diagnosis.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.